On 18 May 2016, the FDA granted accelerated approval to atezolizumab, a PD-L1-targeting mAb, for use in patients with bladder cancer with locally advanced or metastatic bladder cancer who have disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy [20]. This evidence concerns the gene CD274 and urinary bladder carcinoma.